This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?
by Zacks Equity Research
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
Best Growth Stocks to Buy for March 8th
by Zacks Equity Research
POWL, CAH and PAGS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 8, 2023.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact
by Zacks Equity Research
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales
by Zacks Equity Research
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40
by Zacks Equity Research
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
Here's Why You Should Hold on to Neogen (NEOG) Stock Now
by Zacks Equity Research
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPUS
Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable
by Zacks Equity Research
Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.
DaVita (DVA) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
DaVita (DVA) Expands Operational Footprint Via New Agreement
by Zacks Equity Research
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth
by Zacks Equity Research
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stryker (SYK) Completes First Arthroplasty Surgery in Europe
by Zacks Equity Research
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval
by Zacks Equity Research
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
The Zacks Analyst Blog Highlights The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works
by Zacks Equity Research
The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works are included in this Analyst Blog.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like PPC, SUN, CAH and TXT are seeing price strength and have a high chance of carrying the momentum forward.
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
by Zacks Equity Research
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
Best Growth Stocks to Buy for March 6th
by Zacks Equity Research
PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 6, 2023.